Generic Name: lenacapavir

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Capsid Inhibitors

Company: Gilead Sciences

Approval Status: Approved

Generic Version Available: No

Experimental Code: GS-6207

Drug Indication

Sunlenca (lenacapavir) is a long-acting injectable HIV medication. It is approved for treatment experienced people with multidrug-resistant virus who are currently on a failing regimen. It must be used in combination with other antiretrovirals.

Senlenca is not yet included in the U.S. Department of Health and Human Services Antiretroviral Guidelines for Adults and Adolescents.

Visit for the full DHHS guidelines.

General Info

Sunlenca is a long-acting injectable HIV medication. Approved in December 2022, it is the first HIV capsid inhibitor.

Sunlenca is approved for heavily treatment-experienced adults with multidrug-resistant HIV whose are unable to achieve and maintain viral suppression due to resistance, intolerance or safety considerations. Sunlenca is not a complete regimen, and it must be combined with other antiretrovirals.


Dosing Info:

Sunlenca is a long-acting injectable HIV medication taken every six months. People who wish to use Sunlenca have two initiation options:

Option 1:

Two Sunlenca tablets on Day 1 and Day 2 plus two subcutaneous injections on Day 1.

Option 2:
Two Sunlenca tablets on Day 1 and Day 2, one tablet on Day 8 and two subcutaneous injections on Day 15.

After initiation, Sunlenca is given by injection every six months.

Side Effects

The most common side effects of Sunlenca are nausea and injection site reactions, such as pain, redness or swelling.

Drug Interactions

For a review of drug interactions, including prescription and over-the-counter medications and supplements that should not be taken with Sunlenca or may require dose adjustments, consult the Sunlenca package insert.

Other Info

For More Info:

Last Reviewed: December 23, 2022